Retatrutide misinformation tracker: claims vs evidence

Most of what circulates about retatrutide online is a mix of real trial results and claims that have never been checked. This page takes the thirteen we see most often and puts each one next to the evidence. Verdicts are cited. Where the honest answer is "nobody knows", we say that, because sometimes that is the point.

The claims

"It's the same as the trial drug"

What the evidence says: Lilly does not sell retatrutide to anyone outside its trials, so no online product came from the manufacturer.^[1] Independent testing of 18 products sold as retatrutide in 2026 found only one matched its label; about 30% were over-strength, about 30% under, and one contained none at all. The peptide was typically about 10% of the vial's contents, with the remaining 90% unaccounted for.^[2]

Verdict: False. It is a different product with the same name on the label. See what is actually in the vials.

"99% pure means it's safe"

What the evidence says: three online semaglutide vials labelled 99% pure tested at 7.7% to 14.4%, and all contained bacterial endotoxin.^[6] A retatrutide vial tested at 16.6% purity while containing nearly double its labelled strength.^[7] A liver specialist treating the Australian cases said purity testing "doesn't actually tell them if there's any other contaminants or any other drugs or medications that could be mixed with them".^[2]

Verdict: False. Purity, when it is even real, describes the peptide fraction. Safety depends on strength, sterility, contaminants and the other 90%.

"There's a COA, so it's been tested"

What the evidence says: a certificate of analysis describes one sample, chosen by the seller, tested for whatever was asked, on one date. It does not test your vial, does not test for endotoxin or contaminants unless commissioned, and can be copied or edited. The tested products that failed their labels were sold with paperwork.^[2]

Verdict: Misleading. A COA is a claim, not a check. See why a COA doesn't make it safe.

"'Not for human consumption' is just a formality"

What the evidence says: the label exists so the seller can argue they were not supplying a medicine. It does not change what the product does when injected, and the MHRA has said that products sold in the UK claiming to contain retatrutide "are likely to be illegal and are potentially dangerous to people's health".^[8] Under the Human Medicines Regulations, an unlicensed medicine cannot be sold, supplied or advertised for human use, whatever the sticker says.^[3]

Verdict: False. The label protects the seller, not you. It is also an admission that the product was never checked for use in people.

"It's legal because it's not a controlled drug"

What the evidence says: retatrutide is not listed under the Misuse of Drugs Act 1971, so possessing it is not a criminal offence.^[9] But medicines law is separate. Selling, supplying or advertising an unlicensed medicine for human use is an offence under the Human Medicines Regulations 2012, which is what the MHRA's raids and prosecutions rest on.^[3][8]

Verdict: Half true. You are not committing a crime by having it. Whoever sold it to you is. See is it legal in the UK?

"It beats Mounjaro"

What the evidence says: the headline numbers are larger. TRIUMPH-1 reported 25.0% average weight loss at the highest dose over 80 weeks against 3.9% on placebo.^[10] But that trial had different people, a different length and different statistics from the tirzepatide trials, so the figures are not directly comparable. The only fair test, TRIUMPH-5, randomises people between the two drugs and has not reported.^[4]

Verdict: Unproven. A head-to-head is pending. And even if it wins, that applies to the trial product, not to a vial of unknown strength. See how to read a trial.

"Side effects mean it's working"

What the evidence says: in TRIUMPH-1, 14.8% of people on placebo reported nausea, so feeling sick is not proof of anything.^[10] Meanwhile the symptoms of the Australian liver injuries, tiredness, jaundice, dark urine and bruising, were signs of harm, not of a drug doing its job.^[11]

Verdict: False, and dangerous when it is used to talk someone out of seeing a doctor. Side effects mean something is happening. What, and from what, is the question.

"You can't overdose on a peptide"

What the evidence says: a vial labelled 10 mg contained about 19 mg. The gastroenterologist who reported it said "the potential for overdose is enormous", and described a patient losing around eight litres of fluid a day to diarrhoea who could have died without hospital treatment.^[7] Separately, fake weight-loss pens containing insulin, itself a peptide, put people without diabetes into hypoglycaemic coma.^[12]

Verdict: False. Peptides are drugs. Retatrutide's own side effects rise with dose, and the products on sale do not have reliable doses.

"It's approved in the US / China / somewhere"

What the evidence says: Lilly has said it plans to file for US approval in the first quarter of 2027; it has not filed anywhere yet.^[13] The US regulator said in June 2026 that selling retatrutide to consumers is illegal and that it cannot lawfully be compounded.^[14] No regulator in any country has authorised it.^[1]

Verdict: False. Approval anywhere would be global news. See the timeline.

"Lilly is about to launch it"

What the evidence says: filing is planned for early 2027, a regulatory review typically takes around a year, and the UK runs its own process after that. For comparison, orforglipron was authorised by the MHRA in August 2026, about four months after its US approval, and still needs a NICE decision before NHS use.^[13][15] Nothing about a launch changes what is in the vials being sold now.

Verdict: Not soon. A UK licence before 2027 to 2028 is unrealistic (our estimate), and NHS access would come later still.

"The liver-failure cases were something else, not reta"

What the evidence says: the Victorian health department said the presentation suggested "additional contaminants may be contributing", and the treating specialist said "we don't know what these things are".^[11][16] In trials of the real drug, serious liver injury was not a pattern; about 1% had temporary enzyme rises.^[17]

Verdict: Unknown, and that is the point. It may well have been a contaminant rather than retatrutide. But the people who were harmed had no way of knowing what was in their vial, and neither does anyone using the same products now. "It wasn't the drug" is not reassurance; it is the problem. See the liver-injury cluster.

"Doctors prescribe it privately in the UK"

What the evidence says: there is no licensed retatrutide product, and Lilly supplies it only to trials.^[1] Any clinic offering it would have to obtain an unlicensed product from an unknown maker, which is the same supply chain the MHRA has been raiding.^[8] An unlicensed medicine cannot lawfully be sold or supplied for human use.^[3]

Verdict: False. A private prescription does not create a legitimate source. What UK doctors can prescribe is covered on talking to your GP and NHS and licensed options.

"Hair loss means it's fake"

What the evidence says: Wegovy, a licensed drug in the same class, lists hair loss as a common side effect in its UK product information, at 2.5% against 1.0% on placebo.^[5] The NHS lists weight loss itself as a cause of temporary hair loss.^[18]

Verdict: False. Hair shedding a few months into rapid weight loss is expected whatever caused the weight loss. It says nothing about whether a product is genuine, and nothing sold online is genuine anyway. See what people report.

"It's fine, loads of people use it"

What the evidence says: the MHRA seized more than 2,000 finished retatrutide and tirzepatide pens at one site, with tens of thousands of empties waiting to be filled.^[8] Wide use of a product with no quality control means more people exposed, not more evidence of safety. The Australian cases appeared among a population that had also been told it was fine.^[11]

Verdict: Not an argument. Popularity is a measure of marketing, not of what is in the vial.